Therapies that boost anti-HER2 immunity may help reduce risk of HER2-positive breast cancer recurrence

Recurrence of HER2-positive breast cancer after treatment may be due to a specific and possibly cancer-induced weakness in the patient’s immune system — a weakness that in principle could be corrected with a HER2-targeted vaccine — according to a new study from the Perelman School of Medicine at the University of Pennsylvania.